Anti-mpo human igg monoclonal antibody and application thereof
By preparing anti-MPO human IgG monoclonal antibodies with specific amino acid and nucleotide sequences, the problems of scarce sources and large batch-to-batch variability of MPO-ANCA quality control materials have been solved, realizing the reliability and comparability of MPO-ANCA detection and supporting the accuracy of AAV diagnosis and treatment.
CN122103348APending Publication Date: 2026-05-29BEIJING HOSPITAL
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BEIJING HOSPITAL
- Filing Date
- 2026-02-14
- Publication Date
- 2026-05-29
Smart Images
Figure FT_1 
Figure FT_2 
Figure SMS_1
Abstract
The application discloses an anti-MPO human IgG monoclonal antibody and application thereof. Amino acid sequences of CDR1, CDR2 and CDR3 in a heavy chain variable region of the anti-MPO human IgG monoclonal antibody are sequentially shown as SEQ ID No. 1 26-33, 51-58 and 97-111, and amino acid sequences of CDR1, CDR2 and CDR3 in a light chain variable region are sequentially shown as SEQ ID No. 2 26-34, 52-54 and 91-102. Experiments prove that the monoclonal antibody not only has good binding activity with MPO, with a Kd of 0.0088 nM and an EC50 of 1.33 ng / mL, but also has good universality and stability, and can be used as MPO-ANCA quality control instead of a clinical positive sample, and then used for AAV diagnosis, activity evaluation and treatment effect monitoring.
Need to check novelty before this filing date? Find Prior Art